Clinical Pharmacists Co-Author JAMA COVID-19 Pharmacologic Treatment Review

Submitted By:

In the midst of rapidly emerging COVID-19 data from multiple sources, it is imperative that clinicians apply principles of evidence-based medicine and implement pharmacotherapy founded on sound science. Three infectious diseases specialist clinical pharmacists, including ACCP members James M. Sanders, Ph.D, Pharm.D., and Tomasz Z. Jodlowski, Pharm.D., and an infectious diseases specialist physician, collaborated through a private-government partnership to develop institutional guidance for the management of COVID-19 patients, including the safe and judicious use of repurposed therapeutic options. This multidisciplinary, multi-center collaboration led to the development of a focused review of COVID-19 pharmacologic management for frontline providers of all disciplines. The review, “Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19),” was published in the Journal of the American Medical Association (JAMA) online on April 13 and in the May 13, 2020 print issue. It’s been viewed more than 900,000 times on the JAMA website.